Compare RMTI & CPHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RMTI | CPHI |
|---|---|---|
| Founded | 1994 | N/A |
| Country | United States | China |
| Employees | 300 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.7M | 31.2M |
| IPO Year | 2022 | 2008 |
| Metric | RMTI | CPHI |
|---|---|---|
| Price | $5.59 | $0.56 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $2.00 | N/A |
| AVG Volume (30 Days) | ★ 269.2K | 17.9K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | N/A |
| Revenue | ★ $69,258,000.00 | $4,144,268.00 |
| Revenue This Year | $8.64 | N/A |
| Revenue Next Year | $8.44 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.55 | $0.38 |
| 52 Week High | $6.14 | $2.00 |
| Indicator | RMTI | CPHI |
|---|---|---|
| Relative Strength Index (RSI) | 84.63 | 38.01 |
| Support Level | $0.82 | $0.54 |
| Resistance Level | N/A | $0.68 |
| Average True Range (ATR) | 0.25 | 0.11 |
| MACD | 0.48 | -0.01 |
| Stochastic Oscillator | 90.52 | 4.45 |
Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, acid, and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate, among others. The company delivers the majority of its hemodialysis concentrates products and mixers to dialysis clinics throughout the United States and internationally, utilizing its own delivery trucks and third-party carriers.
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection, and others.